Transfer of Responsibility for Oncology Drugs from Pharmacare to BCCA

- Benefit Drug List – Cabergoline, exemestane
- Protocol Update – BRAJCEF, BRAVDOC, BRAVEXE, BRAVTAX, CNB, CNCAB, GIFUA, HNFUFA, LYHDMTXP, LYHDMTXR, LYIT, MOIT
- Cancer Management Manual
- Pre-Printed Order Update – BRAJAC, (U)BRAJACT, BRAJCAF, BRAVAC, BRAVCAD, BRAVDOC, BRAVPAM, BRNFCAF, BRLA2, GIA, UGIRINALT, GOEP, HNFUFA, LYCHOP, LYCHOP-R, LYCOPP, LYCVP, LYECV, LYODBEP, LYRITUX, SAVAC, BRAVAC, BRAVCAD
- Patient Education – Exemestane
- Drug Update – Procarbazine
- Cancer Drug Manual
- Provincial Systemic Therapy Program Policies – Physician Coverage for Medical Emergencies During Delivery of Selected Chemotherapy Drugs (Patient Care Policy III-60)
- Library/Cancer Information Centre
- Acknowledgment of Support

FAX request form and IN TOUCH phone list are provided if additional information is needed.

**Benefit Drug List**

The following new program has been funded by the Provincial Systemic Therapy Program effective 1 July 2001:

- **Cabergoline** for therapy of prolactinoma
- **Exemestane** for hormonal therapy for post-menopausal metastatic breast cancer

Cabergoline is now approved as Class II drug and exemestane as a Class I drug on the benefit list. A Class II form must be completed and submitted to the Provincial Systemic Therapy Program before the cabergoline will be dispensed at a regional cancer centre or reimbursed to a community hospital.

Susan O’Reilly, MB, FRCPC
Provincial Systemic Program Leader

The current Benefit Drug List and Class II forms are available on the website www.bccancer.com.

**Protocol Update**

**Protocols by Drugs Index** A cross-referenced index has been created which lists the BCCA benefit drugs with their corresponding protocols. This index can be obtained via H-drive at regional cancer centres or Fax-back as listed at the end of the Update.

Protocol codes for treatments requiring “Undesignated Indication” approval prior to use are prefixed with the letter U.

**INDEX to BCCA Protocol Summaries** revised monthly (includes tumour group,
protocol code, indication, drugs, last revision date and version)

- **BRAJCEF** revised (tests, dose modifications, precautions): Adjuvant therapy for breast cancer using cyclophosphamide, epirubicin and fluorouracil
- **BRAVDOC** revised (eligibility): Palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide
- **BRAVEXE** new: Palliative therapy for advanced breast cancer using exemestane
- **BRAVTAX** revised (eligibility): Palliative therapy for metastatic breast cancer using paclitaxel
- **CNB** revised (added visual tests, dose titration, dose modifications): Suppressive therapy for prolactinomas using bromocriptine
- **CNCAB** new: Second line suppressive therapy for prolactinoma using cabergoline
- **GIFUA** revised (warfarin added in precautions): Curative combined modality therapy for carcinoma of the anal canal using mitomycin, infusional fluorouracil and radiation therapy
- **HNFUFA** revised (contact physician): 5-Fluorouracil and leucovorin for recurrent head and neck cancer
- **LYHDMTXP** revised (cotrimoxazole dose): Treatment of primary intracerebral lymphoma with high dose methotrexate
- **LYHDMTXR** revised (cotrimoxazole dose): Treatment of leptomeningeal lymphoma or recurrent intracerebral lymphoma with high dose methotrexate
- **LYIT** revised (intrathecal policy added): Treatment of lymphoma using intrathecal methotrexate and cytarabine
- **MOIT** revised (intrathecal policy added): Solid tumours using intrathecal methotrexate and/or thiopeta and/or cytarabine

Most protocols are available on the BCCA website [www.bccancer.bc.ca/ccp/](http://www.bccancer.bc.ca/ccp/).

**Cancer Management Manual**
The Cancer Management Manual is available on BCCA website [www.bccancer.bc.ca/cmm/](http://www.bccancer.bc.ca/cmm/).

---

**Pre-Printed Order Update**
Pre-printed orders should always be checked with the most current BCCA protocol summaries. The Vancouver Cancer Centre has prepared the following chemotherapy pre-printed orders, which can be used as a guide for reference:

- **BRAJAC** (pre-printed order entitled BRAC) revised (labs and bookings): Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide
- **(U)BRAJACT** (pre-printed order entitled BRAC) revised (labs and bookings): Adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel
- **BRAJCAF** (pre-printed order entitled BRCAF) revised (bookings and labs): Adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRAVAC** (pre-printed order entitled BRAC) revised (labs and bookings): Palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide
- **BRAVCAF** (pre-printed order entitled BRCAF) revised (bookings and labs): Palliative therapy for metastatic breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRAVPAM** revised (appointment and treatment section): Treatment of acute bone pain secondary to breast cancer metastases using pamidronate
- **BRINFCAF**(pre-printed order entitled BRCAF) revised (bookings and labs): Therapy for inflammatory breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **BRLA2** (pre-printed order entitled BRCAF) revised (bookings and labs): Therapy for locally advanced breast cancer using cyclophosphamide, doxorubicin and fluorouracil
- **GIA** revised (labs and bookings): Palliative therapy for hepatoma using doxorubicin
- **UGIIRINALT** new: Second-line treatment for 5-FU refractory metastatic colorectal cancer using weekly scheduled irinotecan
- **GOEP** revised (labs and bookings section): Therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide
• **HNFUFA** revised: 5-Fluorouracil and leucovorin for recurrent head and neck cancer
• **LYCHOP** revised (vincristine dose): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone
• **LYCHOP-R** revised (vincristine dose, rituximab preparation): Treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab
• **LYCOPP** revised (vincristine dose): Treatment of Hodgkin’s disease using cyclophosphamide, vincristine, procarbazine and prednisone
• **LYCVP** revised (doses revised): Advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone
• **LYECV** revised (vincristine dose): Consolidation for lymphoma using etoposide, cyclophosphamide and vincristine
• **LYODBEP** revised (vincristine dose): Treatment of Hodgkin’s disease with vincristine, doxorubicin, bleomycin, etoposide and prednisone
• **LYRITUX** revised (rituximab preparation): Treatment of lymphoma with single agent rituximab
• **SAVAC** revised (prn medication corrected): Adjuvant therapy for newly diagnosed Ewing’s sarcoma/peripheral neuroectodermal tumor or rhabdomyosarcoma using vincristine, Adriamycin and cyclophosphamide

An index to the orders can be obtained by Fax-back.

**PATIENT EDUCATION**

Exemestane patient handout is now available via H-drive at regional cancer centres or Fax-Back.

Patient handouts are available for a number of cancer drugs not in the BCCA Cancer Drug Manual or on the BCCA website, and for a number of BCCA treatment protocols. These are listed at the end of the Update and can be obtained via H-drive at regional cancer centres or Fax-back.

**DRUG UPDATE**

**Procarbazine Shortage** There is a worldwide shortage of procarbazine and the stock on hand in all 4 regional cancer centres has expired at the end of June. The manufacturer cannot provide a new supply until the end of July. The BCCA Lymphoma and Neuro-oncology Tumour Groups recommend the following interim measures:

• **CNMOPDCV**: use expired stock on all current patients to complete their courses. New patients should be started on CNCCNU or CTNEMOZ as alternatives to CNMOPDCV.
• **LYPALL**: choose another alternative agent on the list
• **LYCOPP**: replace procarbazine by 5 days of etoposide with 50 mg/m² IV on day 1 and 100 mg/m² PO on day 2 through 5.

**CANCER DRUG MANUAL**

The Cancer Drug Manual is available on the BCCA website [www.bccancer.bc.ca/cdm/](http://www.bccancer.bc.ca/cdm/).

**PROVINCIAL SYSTEMIC THERAPY PROGRAM POLICIES**

**Physician Coverage for Medical Emergencies During Delivery of Selected Chemotherapy Drugs** This patient care policy (III-60) has been developed and being implemented at the regional cancer centres to ensure safe management of medical emergencies arising during chemotherapy treatments.

BCCA Systemic Therapy Policies are available at [h:\everyone\systemic\prov\chemo\policies](h:\everyone\systemic\prov\chemo\policies) on the H-drive at the regional cancer centres and on [www.bccancer.bc.ca/ccp/appendices.shtml](http://www.bccancer.bc.ca/ccp/appendices.shtml) in the BCCA website.

**LIBRARY/CANCER INFORMATION CENTRE**

**Unconventional Cancer Therapies Manual** is available on the BCCA website [www.bccancer.bc.ca/uct/](http://www.bccancer.bc.ca/uct/). The manual consists of 46 short monographs on the more popular alternative cancer therapies, and includes tips for the patient and family on how alternative therapies can be evaluated. For each therapy (e.g., Essiac, vitamins, teas, shark cartilage, etc.), the manual provides proponent/advocate claims, balanced by evidence-based professional evaluation/critique quotations from the literature.
ACKNOWLEDGEMENT OF SUPPORT

Partnership with Abbott Laboratories  The Systemic Therapy Program is pleased to announce the establishment of a long term partnership with Abbott Laboratories. A feature of the partnership is support for an Outcome Analyst for the Genitourinary Tumour Group to assist their activities in analyzing the results, trends, and impacts of current and proposed treatments.

Partnership with AstraZeneca  The Systemic Therapy is pleased to acknowledge our ongoing partnership with AstraZeneca. Their continued support has contributed to the revision and continuing management of the Cancer Drug Manual. New Cancer Drug Manual monographs will be posted on the BCCA website within the next month.

Editorial Review Board

Mário de Lemos, PharmD (Editor)

Sharon Allan, MD
Sandi Broughton, BA(Econ), MSc
Jack Chritchley, MD
Karen Janes, MSN
Susan Walisser, BSc(Pharm)
David Noble, BSc, BLS

Gigi Concon (Secretary)
### BCCA SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

**FAX (604) 877-0585**

**bulletin@bccancer.bc.ca**

**TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247**

**FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247 OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247**

**PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES**

*I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:*

- [ ] E-mail (Word 6.0)
- [ ] Fax

**UPDATES**  Please ☒ Fax-Back information below:

| All items |
| --- | --- | --- |
| anagrelide | BRAVCMF | octreotide (Sandostatin LAR) |
| anastrozole | BRAVTAM | pamidronate |
| Bicalutamide | cabergoline | raltitrexed |
| BRAJAC | capcitabine | rituximab |
| BRAJCAF | clodronate | temozolomide |
| BRAJCEF | docetaxel (Taxotere) | thalidomide |
| BRAJCMF | exemestane | topotecan |
| BRAJCMFPO | gemcitabine | trastuzumab (Herceptin) |
| BRAJTFAM | irinotecan | vinorelbine |
| BRAVCAF | letrozole | |

**Pre-Printed Orders:**

- [ ] BRAJAC  GIA  LYCOPP
- [ ] (U)BRAJACT  UGIRINALT  LYCVP
- [ ] BRAJCAF  GOEP  LYECV
- [ ] BRAVAC  HNFUFA  LYODBEP
- [ ] BRAVPAM  LYCHOP  LYRITUX
- [ ] BRINFCAF  LYCHOP-R  SAVAC
- [ ] BRLA2

**Index: Pre-Printed Orders**

**Protocol Summaries:**

- [ ] BRAJCEF  CNB  LYHDMTXP
- [ ] BRAVDOC  CNCAB  LYHDMTXR
- [ ] BRAVEXE  GIFUA  LYIT
- [ ] BRAVTAX  HNFUFA  MOIT

**Index: Protocol Summaries (current month)**

**Index: Protocols by Drugs Index**

**Reimbursement**

- [ ] Benefit Drug List (01 July 2001)
- [ ] Class 2 Form (01 July 2001)

**Systemic Therapy Update Index**

- [ ] Jan-Dec 2000
- [ ] Jan-Jun 2001
# REGIONAL CANCER CENTRE ACCESS

## BULLETIN UPDATES

<table>
<thead>
<tr>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>H\everyone\systemic\chemo\Pt_Educ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Handouts:</th>
</tr>
</thead>
</table>
| Anagrelide (BRAVC)
| Octreotide (Sandostatin) (BRAVC)
| Anastrozole (BRAVTAM)
| Pamidronate (BRAVTAM)
| Bicalutamide (BRAJAC)
| Cabergoline (BRAJAC)
| Raltitrexed (BRAJAC)
| Capecitabine (BRAJAC)
| Rituximab (BRAJAC)
| Clodronate (BRAJCAF)
| Temozolomide (BRAJCAF)
| Docetaxel (BRAJCEF)
| Thalidomide (BRAJCEF)
| Exemestane (BRAJCMF)
| Topotecan (BRAJCMF)
| Imeritabine (BRAJCMF)
| Trastuzumab (BRAJCMF)
| Vinorelbine (BRAJCMF)
| Letrozole (BRAJCMF)

<table>
<thead>
<tr>
<th>Pre-Printed Orders</th>
</tr>
</thead>
<tbody>
<tr>
<td>H\everyone\systemic\chemo\Orders\VCC</td>
</tr>
</tbody>
</table>

### Index of Pre-Printed Orders

<table>
<thead>
<tr>
<th>BRAJAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRLA2</td>
</tr>
<tr>
<td>LYCOPP</td>
</tr>
</tbody>
</table>

### Protocol Summaries

<table>
<thead>
<tr>
<th>Protocol Summaries</th>
</tr>
</thead>
<tbody>
<tr>
<td>H\everyone\systemic\chemo\Protocol&quot;tumour site&quot;</td>
</tr>
</tbody>
</table>

### Reimbursement

<table>
<thead>
<tr>
<th>Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>H\everyone\systemic\chemo\Reimburs</td>
</tr>
</tbody>
</table>

For easy access, double-click your systemic chemo icon.

We appreciate your comments. Write us at bulletin@bccancer.bc.ca